UPDATE: Citi Upgrades Mylan (MYL) to Buy

(updated to add analyst comment)

Citi upgraded Mylan (NASDAQ: MYL) from Neutral to Buy with a price target of $42.00 (from $36.00).

Analyst Liav Abraham sees optionality on differentiated and durable generics portfolio and likes the broad pipeline of complex generics/biosimilars. The analyst views MYL as best positioned to execute in a challenging environment.

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $30.13 yesterday.

You May Also Be Interested In

• William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
• BofA Securities Reinstates Zoom Video (ZM) at Buy
• Jefferies Upgrades Mirvac Group (MGR:AU) (MRVGF) to Buy